Legato Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Legato Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-43,553	Closed	-$620K	–	788
2025 Q4	$620K	Buy	43,553 +3,342	+8%	+$32.8K	0.05%	490
2025 Q3	$317K	Buy	40,211 +10,934	+37%	+$77.8K	0.03%	486
2025 Q2	$168K	Buy	29,277 +7,721	+36%	+$49.8K	0.02%	525
2025 Q1	$176K	Sell	21,556 -63,583	-75%	-$588K	0.02%	517
2024 Q4	$802K	Sell	85,139 -16,564	-16%	-$172K	0.1%	340
2024 Q3	$1.09M	Hold	101,703	–	–	0.13%	282
2024 Q2	$1.01M	Buy	101,703 +91,153	+864%	+$936K	0.14%	255
2024 Q1	$124K	Hold	10,550	–	–	0.02%	541
2023 Q4	$150K	Hold	10,550	–	–	0.02%	539
2023 Q3	$128K	Buy	+10,550	New	+$136K	0.02%	523

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Legato Capital Management's FOLD Position: Q1 2026 in Review

Legato Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 43,553 shares — an estimated $620K sold.

Legato Capital Management first reported a position in FOLD in Q3 2023 and held it in 10 quarters. The position peaked at $1.09M in Q3 2024. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Legato Capital Management reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Legato Capital Management sold 43,553 Amicus Therapeutics shares in Q1 2026, an estimated $620K.
Legato Capital Management first reported a position in Amicus Therapeutics in Q3 2023 and held it in 10 quarters.
Legato Capital Management's Amicus Therapeutics position peaked at $1.09M in Q3 2024.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.